Core Viewpoint - The article highlights the recent funding and technological advancements of Shanghai Ruisi Health Technology Co., Ltd. (Ruisi Technology), focusing on its innovative solutions for myopia prevention and control among children and adolescents [2][4][6]. Company Overview - Ruisi Technology, established in 2017, specializes in myopia prevention for children and adolescents, utilizing AI-driven technologies that integrate artificial intelligence, optical engineering, and neuroscience [6]. - The company has developed proprietary technologies, including AI light-eye-brain neural regulation, and holds multiple intellectual properties, including 84 trademarks and 58 patents [6]. Recent Financing - On June 30, 2025, Ruisi Technology completed a multi-million A2 round of financing, led by Jinke Jun Chuang, with funds allocated for product development, medical device registration, and market expansion [2][11]. - Previous financing rounds include a 50 million RMB A round in December 2022 and a billion-level A+ round in March 2024, aimed at advancing clinical trials for myopia prevention products [11]. Product and Technology - Ruisi Technology's core products include the Vision Training Instrument D1 and MAX 2.0, which utilize advanced algorithms for real-time focus adjustment based on user needs [6][7]. - The company's far-view light screen product is a pioneering intelligent terminal for myopia prevention, employing digital defocus and AR technology [6][7]. Clinical Validation - Clinical studies have shown that Ruisi Technology's far-view light defocus digital technology significantly slows myopia progression, with a 50% reduction in eye axis elongation and an 80% decrease in myopia degree in trial groups [8]. - The company has established its products in over 400 cities across China and has partnered with over 600 professional institutions [8]. Industry Standards - Ruisi Technology has played a key role in setting industry standards, collaborating with Wenzhou Medical University to publish technical specifications for far-view electronic display terminals in June 2025 [8].

睿视科技成立于 2017年， 独创 AI光眼脑神经调控技术，融合人工智能、光学工程与神经科学、眼 视光临床等交叉学科领域，聚焦动态离焦、光生物、近视离焦、对比度等关键维度，研发数字化调控 利刃，驱动远像技术及整套近视管理数字技术创新。 将防控产品深度融入儿童青少年每日生活高频用眼场景。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 据 IPO早知道消息， 近日， 上海睿视健康科技有限公司 （下称 "睿视科技"） 宣布完成数千万元 A2轮融资，由金科君创独家投资 ， 凯乘资本担任独家财务顾问 。此次融资将重点用于公司核心产 品的研发迭代，三类医疗器械注册申报 的加速以 及市场渠道拓展。 睿视科技在 2025视觉健康创新发展国际论坛（VisionChina2025） 上联合温州医科大学附属眼视 光医院发布《远像电子显示终端技术规范》和《显示产品视觉健康技术要求 ——远像电子显示终 端》两项团体标准。 首创远像数字离焦技术 ， 构建全栈壁垒 睿视科技的 产品包括视力训练仪 D1、视力训练仪MAX2.0、远像光屏PLUS2.0等自主研发生产的 远像类产品，内置睿视科技自主开发的远像光离焦数 ...